Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Net Margin (2016 - 2025)

Perspective Therapeutics' Net Margin history spans 15 years, with the latest figure at 97.42% for Q2 2024.

  • For Q2 2024, Net Margin rose 1058.0% year-over-year to 97.42%; the TTM value through Sep 2025 reached 167.43%, up 619.0%, while the annual FY2024 figure was 67.5%, 56381.0% up from the prior year.
  • Net Margin for Q2 2024 was 97.42% at Perspective Therapeutics, up from 155.07% in the prior quarter.
  • Across five years, Net Margin topped out at 105.73% in Q4 2023 and bottomed at 236.92% in Q3 2022.
  • The 5-year median for Net Margin is 52.26% (2020), against an average of 63.38%.
  • The largest annual shift saw Net Margin crashed -14944bps in 2022 before it soared 21084bps in 2023.
  • A 5-year view of Net Margin shows it stood at 36.8% in 2020, then plummeted by -55bps to 56.96% in 2021, then tumbled by -316bps to 236.92% in 2022, then soared by 145bps to 105.73% in 2023, then plummeted by -192bps to 97.42% in 2024.
  • Per Business Quant, the three most recent readings for CATX's Net Margin are 97.42% (Q2 2024), 155.07% (Q1 2024), and 105.73% (Q4 2023).